Maze Therapeutics (MAZE) EBT Margin (2024 - 2026)
Maze Therapeutics (MAZE) posted EBT Margin of 97.98% for Q1 2026, down 600.48% sequentially from 19.58% in Q4 2024.
Powered by 
Analysis
Maze Therapeutics (MAZE) EBT Margin (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported EBT Margin for 2 years, with the latest figure at 97.98% in Q1 2026.
- Quarterly EBT Margin changed N/A year-over-year to 97.98% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 589.64% (down 55030.0% YoY) and the FY2024 annual result came in at 356.02%, changed N/A from the prior year.
- EBT Margin declined to 97.98% in Q1 2026 per MAZE's latest filing, from 19.58% in the prior quarter.
- Over five years, EBT Margin peaked at 938.55% in Q2 2024 and troughed at 1001.24% in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Maze Therapeutics | 1.55 Bn | 1.55 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -121.04% |
| Sep 30, 2024 | -1,001.24% |
| Jun 30, 2024 | 85.32% |